Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brexpiprazole + escitalopram
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**brexpiprazole + escitalopram** is a combination of two pharmaceutical drugs: brexpiprazole, an atypical antipsychotic, and escitalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. This combination is used as adjunctive therapy in major depressive disorder, particularly in patients who have not responded adequately to antidepressant monotherapy. - **Brexpiprazole** acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A and adrenergic α1B/2C receptors, modulating dopaminergic, serotonergic, and noradrenergic pathways[2][7][3]. - **Escitalopram** inhibits the reuptake of serotonin (5-HT), increasing serotonin levels in the synaptic cleft and enhancing serotonergic neurotransmission. This combination targets multiple neurotransmitter systems (dopamine, serotonin, noradrenaline) for a broader therapeutic effect, potentiating the antidepressant and anxiolytic response in depression and potentially in post-traumatic stress disorder (PTSD)[3][9][7][1].
- Other names
- brexpiprazole + escitaloprambrexpiprazole plus escitalopramescitalopram plus brexpiprazole
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HRH1 (Histamine H1 Receptor)ADRA2C (α2C)M1 (Muscarinic acetylcholine receptor M1)ADRA1B (α1B)HTR7 (5-hydroxytryptamine receptor 7)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on brexpiprazole + escitalopram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brexpiprazole + escitalopram.